Experimental treatment of antipsychotic-induced movement disorders

References

• BrilesJJRosenbergDRBrooksBARobertsMWDiwadkarVAReview of the safety of second-generation antipsychotics: are they really “atypically” safe for youth and adults?Prim Care Companion CNS Disord201214311r01298
   Google Scholar
• ButlerRRadhakrishnanRDementiaClin Evid201291001
   Google Scholar
• KaneJHonigfeldGSingerJMeltzerHClozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazineArch Gen Psychiatry1988457897963046553
   PubMed Web of Science ®Google Scholar
• FountoulakisKNVietaEEfficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic reviewAnn Gen Psychiatry20098161619635147
   PubMedGoogle Scholar
• DeclercqTPetrovicMAzermaiMWithdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementiaCochrane Database Syst Rev20133CD00772623543555
   PubMed Web of Science ®Google Scholar
• BallardCWaiteJThe effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s diseaseCochrane Database Syst Rev20061CD00347616437455
   PubMedGoogle Scholar
• GeddesJFreemantleNHarrisonPBebbingtonPAtypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ20003211371137611099280
   PubMed Web of Science ®Google Scholar
• LeuchtSWahlbeckKHamannJKisslingWNew generation antipsychotics vs low-potency conventional antipsychotics: a systematic review and metaanalysisLancet2003361581158912747876
   PubMed Web of Science ®Google Scholar
• DavisJMChenNGlickIDA meta-analysis of the efficacy of second-generation antipsychoticsArch Gen Psychiatry20036055356412796218
   PubMed Web of Science ®Google Scholar
• KeefeRSBilderRMDavisSMCATIE InvestigatorsNeurocognitive Working GroupNeurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trialArch Gen Psychiatry20076463364717548746
   PubMed Web of Science ®Google Scholar
• LewisSLiebermanJCATIE and CUTLASS: can we handle the truth?Br J Psychiatry2008192316116318310570
   PubMed Web of Science ®Google Scholar
• AttardATaylorDMComparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?CNS Drugs20122649150822668246
   PubMed Web of Science ®Google Scholar
• HartlingLAbou-SettaAMDursunSAntipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysisAnn Intern Med201215749851122893011
   PubMed Web of Science ®Google Scholar
• PringsheimTDojaABelangerSPattenSTreatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youthPaediatr Child Health20111659059823115503
   PubMed Web of Science ®Google Scholar
• HaddadPMDasAKeyhaniSChaudhryIBAntipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisonsJ Psychopharmacol2012265Suppl152622057019
   PubMedGoogle Scholar
• LiCRChungYCParkTWClozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drugWorld J Biol Psychiatry20091091992419995222
   PubMed Web of Science ®Google Scholar
• HaleemDJShireenEHaleemMASomatodendritic and post-synaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsyProg Neuropsychopharmacol Biol Psychiatry20042881323132915588759
   PubMed Web of Science ®Google Scholar
• HaleemDJSerotonergic modulation of DA neurotransmission: a mechanism for enhancing therapeutics in schizophreniaJCPSP200616855656216899192
   PubMedGoogle Scholar
• HaleemDJSamadNHaleemMAReversal of haloperidol induced extrapyramidal symptoms by buspirone; a time related studyBehav Pharmacol20071814715317351421
   PubMed Web of Science ®Google Scholar
• ShireenENaeemSInamQUHaleemDJOral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in ratsPak J Pharm Sci201326227127623455196
   PubMed Web of Science ®Google Scholar
• ShireenEPervezSMasroorMReversal of haloperidol induced motor deficits in rats exposed to repeated immobilization stressPak J Pharm Sci20142751459146625176240
   PubMed Web of Science ®Google Scholar
• StrawnJRKeckPECaroffSNNeuroleptic malignant syndromeAm J Psychiatry200716487087617541044
   PubMed Web of Science ®Google Scholar
• RayWAChungCPMurrayKTHallKSteinCMAtypical antipsychotic drugs and the risk of sudden cardiac deathN Engl J Med200936022523519144938
   PubMed Web of Science ®Google Scholar
• KnolWvan MarumRJJansenPASouvereinPCSchobbenAFEgbertsACAntipsychotic drug use and risk of pneumonia in elderly peopleJ Am Geriatr Soc20085666166618266664
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)Arch Gen Psychiatry2006631079108717015810
   PubMed Web of Science ®Google Scholar
• AlpayMKoroshetzWJQuetiapine in the treatment of behavioral disturbances in patients with Huntington’s diseasePsychosomatics200647707216384811
   PubMed Web of Science ®Google Scholar
• JohnstonTGRisperidone long-acting injection and Huntington’s disease: case series with significant psychiatric and behavioural symptomsInt Clin Psychopharmacol20112611411921119522
   PubMed Web of Science ®Google Scholar
• Marti-MassoJFCarreraNUrtasunMDrug-induced parkinsonism: a growing list [letter]Mov Disord199381258419801
   PubMed Web of Science ®Google Scholar
• GershanikOSDrug-induced parkinsonism in the aged: recognition and preventionDrugs Aging199451271327981484
   PubMed Web of Science ®Google Scholar
• Perez-GilabertYMateoDGimenez-RoldanSActividad asistencial en una consulta hospital aria especializada en enfermedad de Parkinson y transtornos del movimiento: un estudio prospectivo durante anos [Care activities in a hospital clinic specializing in Parkinson’s disease and movement disorders: a prospective study for years]Neurologia19949317323 Spanish7803048
   PubMedGoogle Scholar
• Jimenez-JimenezFJOrti-ParejaMAyuso-PeraltaLDrug-induced parkinsonism in a movement disorders unit. A four-year surveyParkinsonism Relat Disord1996214514918591033
   PubMedGoogle Scholar
• GrohmannRKochRSchmidtLGExtrapyramidal symptoms in neuroleptic recipientsAgents Actions Suppl19902971821969222
   PubMedGoogle Scholar
• CaseyDETardive dyskinesia: pathophysiology and animal modelsJ Clin Psychiatry2000615910739324
   PubMed Web of Science ®Google Scholar
• KurokiTNagaoNNakaharaTNeuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesisProg Brain Res200817219921218772034
   PubMed Web of Science ®Google Scholar
• HaleemDJBatoolFKhanNHDifferences in the effects of haloperidol and clozapine on rat brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in ratsMed Sci Monit2002833543361
   Google Scholar
• ShireenEHaleemDJReversal of haloperidol-induced motor deficits by mianserin and mesulergine in ratsPak J Pharm Sci201124171221190911
   PubMed Web of Science ®Google Scholar
• PorsoltRDMoserPCCastagnéVBehavioral indices in antipsychotic drug discoveryJ Pharmacol Exp Ther201033363263820200119
   PubMed Web of Science ®Google Scholar
• FardeLNordströmALWieselFAPauliSHalldinCSedvallGPositron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effectsArch Gen Psychiatry1992495385441352677
   PubMed Web of Science ®Google Scholar
• ShinH-WChungSJDrug-induced parkinsonismJ Clin Neurol20128152122523509
   PubMed Web of Science ®Google Scholar
• HaleemDJSamadNHaleemMAReversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in ratsPharmacol Biochem Behav20078711512117498786
   PubMed Web of Science ®Google Scholar
• PrinssenEPKlevenMSKoekWInteractions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effectsPsychopharmacology (Berl)1999144202910379620
   PubMed Web of Science ®Google Scholar
• HaleemDJKhanNHEnhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in ratsProg Neuropsychopharmacol Biol Psychiatry200327464565112787852
   PubMed Web of Science ®Google Scholar
• PrinssenEPColpaertFCKoekW5-HT1A receptor activation and anticataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsyEur J Pharmacol200245321722112398907
   PubMed Web of Science ®Google Scholar
• HaleemDJExtending therapeutic use of psychostimulants: focus on serotonin-1A receptorProg Neuropsychopharmacol Biol Psychiatry20134617018023906987
   PubMed Web of Science ®Google Scholar
• EspositoESerotonin-dopamine interaction as a focus of novel antidepressant drugsCurr Drug Targets2006717718516475959
   PubMed Web of Science ®Google Scholar
• ClemettDAPunhaniTDuxonMSBlackburnsTPFoneKCImmunohistochemical localization of the 5-HT-2C receptor protein in the rat CNSNeuropharmacology200039261263
   Web of Science ®Google Scholar
• KapurSRamingtonGJonesCHigh levels of dopamine D2 receptor occupancy with low dose haloperidol treatment: a PET studyAm J Psychiatry1996153946950
   Web of Science ®Google Scholar
• FaurbyeARaschPJPetersenPBBrandborgGPakkenbergHNeurological symptoms in pharmacotherapy of psychosesActa Psychiatr Scand196440102714217630
   PubMed Web of Science ®Google Scholar
• EganMFApudJWyattRJTreatment of tardive dyskinesiaSchizophr Bull1997235836099365997
   PubMed Web of Science ®Google Scholar
• RevueltaGJCloudLAiaPGFactorSATardive dyskinesiasAlbaneseAJHyperkinetic Movement Disorders: Differential Diagnosis and TreatmentChichesterWiley-Blackwell2012331352
   Google Scholar
• DayaluPChouKLAntipsychotic-induced extrapyramidal symptoms and their managementExpert Opin Pharmacother2008991451146218518777
   PubMed Web of Science ®Google Scholar
• Soares-WeiserKFernandezHHTardive dyskinesiaSemin Neurol200727215916917390261
   PubMed Web of Science ®Google Scholar
• JesteDVCaliguirMPTardive dyskinesiaSchizophr Bull1993193033158100643
   PubMed Web of Science ®Google Scholar
• WaddingtonJLSpontaneous orofacial movements-induced in rodents by very long term-neuroleptic administration: phenomenology, pathophysiology and putative relationship with tardive dyskinesiaPsychopharmacology (Berl)19901014314471975104
   PubMed Web of Science ®Google Scholar
• KulkarniSKNaiduPSAnimal models of tardive dyskinesia-a reviewIndian J Physiol Pharmacol20014514816011480221
   PubMedGoogle Scholar
• MarcheseGCasuMNBartholinicFSubchronic treatment with classical but not atypical antipsychotic produced morphological changes in rat nigrostriatal dopaminergic neurons directly related to early onset vacuous chewingEur J Neurosci2002151187119611982629
   PubMedGoogle Scholar
• ZhangWPerryKWWongDTSynergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine or norepinephrine and DA release in rat prefrontal cortexNeuropsychopharmacology20002325026210942849
   PubMed Web of Science ®Google Scholar
• GershanikOSGómez ArévaloGJTypical and atypical neurolepticsHandb Clin Neurol201110057959921496609
   PubMedGoogle Scholar
• CadetJLKahlerLAFree radical mechanisms in schizophrenia and tardive dyskinesiaNeurosci Biobehav Rev1994184574677708360
   PubMed Web of Science ®Google Scholar
• WrightAMBempongJKirbyMLBarlowRLBloomquistJREffects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesiaBrain Res19987882152229555021
   PubMed Web of Science ®Google Scholar
• NaiduPSSinghAKulkarniSKEffects of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunctionsPhytother Res20062014014616444668
   PubMed Web of Science ®Google Scholar
• JennerPMarsdenCDIs the dopamine hypothesis of tardive dyskinesia completely wrong?Trends Neurosci19869259260
   Web of Science ®Google Scholar
• TurronePRemingtonGNobergaJNThe VCM model of TD revisited: is there a relationship to DA D-2 receptor occupancy?Neurosci Biobehav Rev20022636138012034136
   PubMed Web of Science ®Google Scholar
• ShireenEQurrat-ul-AinBatoolFHaleemDJNeurochemical effects of 8-OH-DPAT in rats treated with haloperidolPak J Pharm Sci2002151718216414870
   PubMedGoogle Scholar
• ShireenEKhanABatoolFHaleemDJIncrease in serotonin-1A receptor responses following haloperidol withdrawalJ Basic Appl Sci2006214554
   Google Scholar
• LevinsonAJGarsideSRosebushPIMazurekMFHaloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the ratNeuroscience1998842012119522374
   PubMed Web of Science ®Google Scholar
• ZhangYXuHHeJQuetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatmentNeurosci Lett2007420667117466452
   PubMed Web of Science ®Google Scholar
• ReynoldsKBMac GillivrayLZettlerMRosebushPIMazurekMFRole of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neuronsBrain Res20111394243221396352
   PubMed Web of Science ®Google Scholar
• BordiaTMcIntoshJMQuikMNicotine reduces antipsychotic-induced orofacial dyskinesia in ratsJ Pharmacol Exp Ther201234061261922144565
   PubMed Web of Science ®Google Scholar
• TauscherJKapurSVerhoeffNPBrain serotonin 5-HT-1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635Arch Gen Psychiatry20025951452012044193
   PubMed Web of Science ®Google Scholar
• GobertARivetJMCisterilliLMelonCMillanMJBuspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin-1A receptors and blockade of alpha-2-adrenergic receptors underlie its activationNeuroscience1999931251126210501449
   PubMed Web of Science ®Google Scholar
• PeroutkaSJSelective interaction of novel anxiolytics with 5-hydroxytryptamine 1A receptorsBiol Psychiatry1985209719792862927
   PubMed Web of Science ®Google Scholar
• QueirozCMFrussa-FilhoREffects of buspirone on an animal model of tardive dyskinesiaProg Neuropsychopharmacol Biol Psychiatry1999231405141810631766
   PubMed Web of Science ®Google Scholar
• NaiduPSKulkarniSKEffect of 5-HT-1A and 5-HT-2A/2C receptor modulation on neuroleptic-induced vacuous chewing movementsEur J Pharmacol2001428818611779040
   PubMed Web of Science ®Google Scholar
• PandyaCDHowellKRPillaiAAntioxidants as potential therapeutics for neuropsychiatric disordersProg Neuropsychopharmacol Biol Psychiatry20154621422323123357
   PubMed Web of Science ®Google Scholar
• ParikhVMohammadMKSahebaraoPMDifferential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brainJ Psychiatr Res2003371435112482469
   PubMed Web of Science ®Google Scholar
• PillaiAParikhVTerryAVMahadikSPLong-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brainJ Psychiatr Res200741537238616564057
   PubMed Web of Science ®Google Scholar
• JenkinsRRGoldfarbAIntroduction-oxidant stress, aging, and exerciseMed Sci Sports Exerc1993252102128450723
   PubMed Web of Science ®Google Scholar
• HalliwelBGutteridgeJMCFree Radicals in Biology and Medicine3rd edOxfordOxford University Press1999
   Google Scholar
• EvansDRParikhVVKhanMMCoussonsCBuckleyPFMahadikSPRed blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatmentProstaglandins Leukot Essent Fatty Acids20036939339914623492
   PubMed Web of Science ®Google Scholar
• SagaraYInduction of reactive oxygen species in neurons by haloperidolJ Neurochem199871100210129721725
   PubMed Web of Science ®Google Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry200416141442514992963
   PubMed Web of Science ®Google Scholar
• TarsyDLunguCBaldessariniRJEpidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugsHandb Clin Neurol201110060161621496610
   PubMedGoogle Scholar
• BhidayasiriRFahnSWeinerWJEvidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of NeurologyNeurology2013846346923897874
   PubMed Web of Science ®Google Scholar
• NazFShireenESuppression and treatment of haloperidol induced extra-pyramidal side effects and anxiety syndrome by the coadministeration of red rice bran oil in ratsInt J Endors Health Sci Res2014228292
   Google Scholar
• NagarjunaSArifullahMKumarASEvaluation of antioxidant and antiparkinsonian activities of Brassica oleracea in haloperidol-induced tardive dyskinesiaInt J Green Pharm201593143149
   Google Scholar
• BishnoiMChopraKKulkarniSKProtective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brainPharmacol Biochem Behav20088851152218022680
   PubMed Web of Science ®Google Scholar
• CloudLJZutshiDFactorSATardive dyskinesia: therapeutic options for an increasingly common disorderNeurotherapeutics201411116617624310603
   PubMed Web of Science ®Google Scholar
• ZhangWFTanYLZhangXYChanRCWuHRZhouDFExtract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry201172561562120868638
   PubMed Web of Science ®Google Scholar
• LernerVMiodownikCKaptsanAVitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover studyAm J Psychiatry20011581511151411532741
   PubMed Web of Science ®Google Scholar
• ZhangXYZhouDFCaoLYXuCQChenDCWuGYThe effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trialJ Clin Psychopharmacol2004241838614709952
   PubMed Web of Science ®Google Scholar